<DOC>
	<DOCNO>NCT02865629</DOCNO>
	<brief_summary>N-acetylcysteine treatment depressive symptom youth high-risk bipolar disorder : functional connectivity study</brief_summary>
	<brief_title>N-acetylcysteine Treatment Depressive Symptoms Bipolar Offspring</brief_title>
	<detailed_description>To conduct 8-week , open label study N-acetylcysteine treatment depressive symptom youth high risk bipolar disorder , rest state functional magnetic resonance imaging ( fMRI ) examination baseline endpoint . This proposal innovative investigates efficacy tolerability novel pharmacological treatment youth offspring bipolar disorder , examine neurophysiology predictor mood disorder youth high risk bipolar disorder . This study obtain pilot data propose large , neuroimaging-based , double-blind , placebo-controlled trial N-acetylcysteine youth high risk bipolar disorder . The expected outcome , N-acetylcysteine efficacious ameliorate depressive symptom youth high risk bipolar disorder , demonstrate improvement functional connectivity within left frontostriatal circuit associate treatment response .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Age 15 year , 0 mo . 24 year , 11 mo . ; For minor , least one parent stepparent/guardian subject live willing participate research session ; For minor , child relative ( ) able willing give write informed assent/consent participate , respectively ; youth meet criteria highrisk : least one first degree relative Bipolar I Disorder , assess Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders DSM ( SCID ) ; youth show evidence current significant depressive symptom determine current Hamilton Depression Rating Scale ( HAMD ) great equal 8 . Inclusion Youth Depressive Anxiety Disorders Comorbid Disorders Although formally require study entry , many youth meet criterion range mood anxiety disorder study entry ( except major depressive disorder , bipolar I II disorder , psychotic disorder , exclusionary ) , formally assess structure diagnostic interview baseline . If course interview becomes apparent participant demonstrate symptomatology and/or rating scale score consistent psychiatric disorder , youth family debrief finding plan develop collaboration patient 's clinician alternative study participation treatment disorder indicate . Presence current lifetime history mood episode ( major depressive episode , mixed , manic , hypomanic ) , psychotic disorder . DSM5 diagnosis autism , pervasive developmental disorder , obsessivecompulsive disorder , posttraumatic stress disorder , Tourette 's disorder , psychotic disorder include schizophrenia ; Drug alcohol abuse dependence disorder 3 month prior study recruitment , although lifetime history substance alcohol disorder present child abstinent least 3 month ( see discussion ) ; Pregnancy ; participant encourage mandate discuss positive pregnancy test guardian ( minor ) follow local law History major neurological disorder ( epilepsy ) , head trauma &gt; 10 minute loss consciousness Evidence mental retardation ( IQ less 70 ) , determine Wechsler Abbreviated Scale Intelligence contraindication MRI , include metal body related injury surgery ( e.g. , surgical clip , metal fragment eye ) , piercings remove , brace , permanent retainer . History allergic reaction Nacetylcysteine History prior exposure antidepressant antipsychotic</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>